- Home
- ECBK vs SPRO Comparison
ECBK vs SPRO Comparison
Compare ECBK & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ECBK
- SPRO
- Stock Information
- Founded
- ECBK 1919
- SPRO 2013
- Country
- ECBK United States
- SPRO United States
- Employees
- ECBK N/A
- SPRO N/A
- Industry
- ECBK Banks
- SPRO Biotechnology: Pharmaceutical Preparations
- Sector
- ECBK Finance
- SPRO Health Care
- Exchange
- ECBK Nasdaq
- SPRO Nasdaq
- Market Cap
- ECBK 151.0M
- SPRO 162.1M
- IPO Year
- ECBK N/A
- SPRO 2017
- Fundamental
- Price
- ECBK $16.11
- SPRO $2.49
- Analyst Decision
- ECBK
- SPRO Buy
- Analyst Count
- ECBK 0
- SPRO 4
- Target Price
- ECBK N/A
- SPRO $5.00
- AVG Volume (30 Days)
- ECBK 67.3K
- SPRO 1.2M
- Earning Date
- ECBK 08-08-2025
- SPRO 08-04-2025
- Dividend Yield
- ECBK N/A
- SPRO N/A
- EPS Growth
- ECBK 17.87
- SPRO N/A
- EPS
- ECBK 0.57
- SPRO N/A
- Revenue
- ECBK $26,906,000.00
- SPRO $44,584,000.00
- Revenue This Year
- ECBK N/A
- SPRO N/A
- Revenue Next Year
- ECBK N/A
- SPRO N/A
- P/E Ratio
- ECBK $28.65
- SPRO N/A
- Revenue Growth
- ECBK 5.99
- SPRO N/A
- 52 Week Low
- ECBK $12.50
- SPRO $0.51
- 52 Week High
- ECBK $16.99
- SPRO $3.22
- Technical
- Relative Strength Index (RSI)
- ECBK 59.98
- SPRO 43.34
- Support Level
- ECBK $15.78
- SPRO $2.89
- Resistance Level
- ECBK $16.45
- SPRO $3.22
- Average True Range (ATR)
- ECBK 0.39
- SPRO 0.14
- MACD
- ECBK 0.10
- SPRO -0.10
- Stochastic Oscillator
- ECBK 85.54
- SPRO 2.01
About ECBK ECB Bancorp Inc.
ECB Bancorp Inc operates as a bank holding company of Everett Co-operative Bank. The firm through its subsidiary engages in business consisting of taking deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential real estate loans, commercial real estate, and multifamily real estate loans, construction and land loans and home equity lines of credit.
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.